Literature DB >> 23806975

Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites.

William C Eckelman1, Alun G Jones, Adriano Duatti, Richard C Reba.   

Abstract

Technetium-99m (Tc-99m) has long been a mainstay in clinical nuclear medicine, primarily monitoring biological processes in the heart, kidney, liver, and brain. More recently, Tc-99m chelates have been used as the reporter in targeted nuclear medicine probes that monitor changes in specific protein expression products. The strengths remain the inexpensive source of Tc-99m from the Mo-99/Tc-99m generator, its rich chemistry, high-yield kit formulation, and its widespread availability. Hardware and software advances, such as OSEM reconstructions with scatter and attenuation corrections, have led to quantitation of the injected radioactivity in terms of kBq/cm.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23806975     DOI: 10.1016/j.drudis.2013.06.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Rational development of radiopharmaceuticals for HIV-1.

Authors:  Chuen-Yen Lau; Frank Maldarelli; William C Eckelman; Ronald D Neumann
Journal:  Nucl Med Biol       Date:  2014-01-17       Impact factor: 2.408

Review 2.  Technetium Complexes and Radiopharmaceuticals with Scorpionate Ligands.

Authors:  Petra Martini; Micol Pasquali; Alessandra Boschi; Licia Uccelli; Melchiore Giganti; Adriano Duatti
Journal:  Molecules       Date:  2018-08-15       Impact factor: 4.411

3.  The synthesis of a 99mTc-labeled tetravalent targeting probe upon isonitrile coordination to 99mTcI for enhanced target uptake in saturable systems.

Authors:  Yuki Mizuno; Tomoya Uehara; Chun-Wei Jen; Hiromichi Akizawa; Yasushi Arano
Journal:  RSC Adv       Date:  2019-08-21       Impact factor: 4.036

Review 4.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.